Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis - Nantes Université
Article Dans Une Revue Infectious Diseases Now Année : 2022

Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis

Résumé

Endocarditis due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae is a rare but challenging condition. Its treatment relies on carbapenems alone or in combination, and no alternative has been described to date. The cephamycin cefoxitin has been used for treatment of mild ESBL-producing Enterobacteriaceae infections.

Dates et versions

hal-04757129 , version 1 (28-10-2024)

Identifiants

Citer

P. Danneels, C. Rihet, C. Vannier, C. Quinqueneau, R. Courtois, et al.. Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis. Infectious Diseases Now, 2022, 52 (7), pp.408-413. ⟨10.1016/j.idnow.2022.08.001⟩. ⟨hal-04757129⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More